Evidence map›Paper›PMID 26747427›Full record

ArticleGlycobiology2016

Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides.

Tsuyoshi Yamada, Yutaka Kanda, Makoto Takayama, Akitoshi Hashimoto, Tsutomu Sugihara, Ai Satoh-Kubota, Eri Suzuki-Takanami, Keiichi Yano, Shigeru Iida, Mitsuo Satoh

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Glycobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Anticoagulant and signaling functions of antithrombin.Journal of thrombosis and haemostasis : JTH · 2020
    Review
  6. Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin.Journal of thrombosis and haemostasis : JTH · 2020
    Article
  7. Article
  8. Comparison of Protective Effects of Recombinant Antithrombin Gamma and Plasma-Derived Antithrombin on Sepsis-Induced Disseminated Intravascular Coagulation and Multiple Organ Failure.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Tsuyoshi YamadaBio Process Research and Development Laboratories, Production Division, Kyowa Hakko Kirin Co., Ltd., Takasaki-shi, Gunma 370-0013, Japan.
Yutaka KandaFuji Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Suntou-gun, Shizuoka 411-8731, Japan.
Makoto TakayamaFuji Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Suntou-gun, Shizuoka 411-8731, Japan.
Akitoshi HashimotoFuji Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Suntou-gun, Shizuoka 411-8731, Japan.
Tsutomu SugiharaBio Process Research and Development Laboratories, Production Division, Kyowa Hakko Kirin Co., Ltd., Takasaki-shi, Gunma 370-0013, Japan.
Ai Satoh-KubotaTokyo Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Machida-shi, Tokyo 194-8533, Japan.
Eri Suzuki-TakanamiTokyo Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Machida-shi, Tokyo 194-8533, Japan.
Keiichi YanoR&D Planning Department, R&D Division.
Shigeru IidaTokyo Research Park, R&D Division, Kyowa Hakko Kirin Co., Ltd., Machida-shi, Tokyo 194-8533, Japan shigeru.iida@kyowa-kirin.co.jp.
Mitsuo SatohImmunology & Allergy R&D Unit, R&D Division, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Tokyo 100-8185, Japan.
Kyowa Kirin (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin-binding affinity. In human plasma, AT circulates as a mixture of the α-form bearing four oligosaccharides and the β-form lacking an oligosaccharide at Asn135. However, it remains unclear how the immature high-mannose-type oligosaccharides produced by mammalian cells affect biological activities of AT. Here, we succeeded in directly comparing the activities between the high-mannose and complex types. Interestingly, although there were no substantial differences in thrombin inhibitory activity, the high-mannose type showed higher heparin-binding affinity. The anticoagulant activities were increased by heparin and correlated with the heparin-binding affinity, resulting in the strongest anticoagulant activity being displayed in the β-form with the high-mannose type. In pharmacokinetic profiling, the high-mannose type showed a much shorter plasma half-life than the complex type. The β-form was found to have a prolonged plasma half-life compared with the α-form for the high-mannose type; conversely, the α-form showed a longer half-life than the β-form for the complex-type. The present study highlights that AT physiological activities are strictly controlled not only by a core fucose at the reducing end but also by the high-mannose-type structures at the nonreducing end. The β-form with the immature high-mannose type appears to function as a more potent anticoagulant than the AT typically found in human plasma, once it emerges in the blood.

Indexed as

Antithrombin ProteinsGlycosylationHeparinHumansMannoseOligosaccharidesProtein BindingAntithrombin ProteinsHeparinMannoseOligosaccharidesanticoagulant activitiesantithrombinheparin-binding affinityhigh-mannose-type N-linked oligosaccharidespharmacokinetics

Identifiers

PMID26747427
PMCPMC4813732
OpenAlexW2228797942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.